However, some trials, like those involving CCR1/AZD4818 for COPD, CCR3/GSK766994 for asthma, and CCL2/Carlumab for IPF, have shown no efficacy [16,150]. This evidence concerns the gene CCL2 and idiopathic interstitial pneumonia.